Asia Tumbles, Tesla...
Health Care: Drugs
ViroPharma Inc. (VPHM: NASDAQ)
$26.60 0.50 | 1.93%
05/23/13 - 12:25 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 26.10 |
| 52 Week High | 31.36 |
| 52 Week Low | 19.58 |
| Avg. Daily Vol. (Mil) | 0.55 |
| Beta (3 year) | 1.43 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,704.62 |
| Shares Out (Mil) | 65.31 |
| Float (Mil) | 38.16 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.20 |
| Current Ratio | 4.50 |
| LT Debt/ Equity | 0.23 |
| Total Debt / Equity | 0.23 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 4.27 |
| Price/Book | 2.43 |
| Price/Cash Flow | -62.50 |
| Per Share Data | |
| Earnings | -1.19 |
| Sales | 6.11 |
| Book Value | 10.73 |
| Cash Flow | -0.42 |
| Business Summary | |
|---|---|
| ViroPharma, Inc. company dedicated to the development and commercialization of products that address serious diseases, with a focus on products used by physician specialists or in hospital settings. | |
| General Information | |
| 730 Stockton Drive
Exton, PA 19341 |
|
| www.viropharma.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 410 | |
| CEO: Vincent J. Milano | |
| Short Interest | |
| Current Month (Mil) | 7.33 |
| Previous Month (Mil) | 7.34 |
| Short Interest Ratio (Days) | 15.70 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -7.10 |
| Return on Investments | -9.10 |
| Profitability | |
| Gross Margin | 77.30 |
| EBIT Margin | -27.60 |
| Profit Margin | -19.60 |
Portfolios with VPHM
- Portfolio NameUser Type
- ProJoel Greenblatt - Gotham Ca...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Userjohnnystocks
- ContributorEarnings Short Squeeze Play...
- UserGFNN Stockdiagnostics 3
- ContributorEarnings Short Squeeze Play...
- ContributorStocks At New 52-Week Highs...
- UserStocks
- ContributorEarnings Short Squeeze Play...
Latest VPHM Headlines from TheStreet
- ViroPharma (VPHM) Shares Cross Above 200 DMA 05.13.13 | 12:05 pm
- 'Mad Money' Lightning Round: Buy More Travelers 04.18.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Haves and Have-Nots 04.17.13 | 08:04 pm
- Bullish Two Hundred Day Moving Average Cross - VPHM 04.12.13 | 05:04 pm
- Cramer's 6 Stocks in 60 Seconds: TRLA LULU EOG BDX CMG VPHM (Update1) 03.27.13 | 05:03 pm
- Cramer's Top Stock Picks: WPRT VPHM TXN JDSU CSC 03.09.13 | 06:03 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 03.08.13 | 07:03 pm
- ViroPharma Inc. Stock Downgraded (VPHM) 11.19.12 | 04:11 am
- 8 Stocks Soaring Higher With Big Volume 09.21.12 | 02:09 pm
- ViroPharma's CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.10.12 | 06:08 pm
Press Releases for VPHM
- ViroPharma To Release 2012 Fourth Quarter And Full Year Financial Results On February 27, 2013 - PR Newswire 02.22.13 | 12:02 pm
- ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences - PR Newswire 02.11.13 | 12:02 pm
- Sub-Group Analysis Of Data From Pediatric Patients With Hereditary Angioedema Published In The Journal Of Pediatrics - PR Newswire 01.16.13 | 08:01 am
- ViroPharma Provides 2013 Outlook - PR Newswire 01.07.13 | 07:01 am
- ViroPharma And Halozyme Therapeutics Announce Initiation Of Phase 2b Dose Ranging Combination Study For Subcutaneous Administration Of Cinryze® (C1 Esterase Inhibitor [human]) With Hyaluronidase (rHuPH20) - PR Newswire 12.19.12 | 07:12 am
- ViroPharma Launches Novel Campaign To Illustrate The Emotional Burden Of Hereditary Angioedema - PR Newswire 12.12.12 | 08:12 am
- ViroPharma To Participate In Two December Healthcare Investor Conferences - PR Newswire 11.29.12 | 04:11 pm
- ViroPharma's Cinryze® (C1 Esterase Inhibitor [Human]) Prophylaxis Study Showed Safety Data Of Escalating Doses In Patients With Hereditary Angioedema - PR Newswire 11.13.12 | 07:11 am
- ViroPharma To Participate In Two November Healthcare Investor Conferences - PR Newswire 11.08.12 | 02:11 pm
- Health Canada Approves New Drug Submission For Cinryze⢠(C1 Inhibitor [human]) - PR Newswire 10.22.12 | 08:10 am
Partner Headlines for VPHM
- Top Mutual Funds Still Nibbling At Ocwen Financial - Investor's Business Daily 02.04.13 | 06:02 pm
- Pertaining to Relief for ViroPharma - Analyst Blog - NASDAQ 09.25.12 | 07:09 pm
- Abbott-Astellas Collaborate - Analyst Blog - Zacks 09.13.12 | 06:09 pm
- ViroPharma Misses Zacks Estimates - Analyst Blog - Zacks 08.10.12 | 09:08 am
- VPHM Manufacturing Process Approved - Analyst Blog - Zacks 08.07.12 | 07:08 pm
- ViroPharma Receives FDA Approval of Cinryze - Benzinga 08.06.12 | 01:08 pm
- Bad News for ViroPharma - Analyst Blog - Zacks 08.03.12 | 06:08 pm
- ViroPharma's Cinryze® (C1 esterase inhibitor [human]) Open Label Prophylaxis Study Showed Up To 2.6 Years Of Effectiveness In Majority Of Subjects - Benzinga 07.27.12 | 09:07 am
- ViroPharma Initiates Phase II Study - Analyst Blog - Zacks 06.05.12 | 07:06 pm
- ViroPharma Falters, Guides Lower - Analyst Blog - Zacks 05.02.12 | 10:05 am
